Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study-Reference-Cited by-同舟云学术

Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study

Published:2019-04-02 Issue:3 Volume:31 Page:222-226
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

del Alcázar Elena¹,Ferran Marta²,López-Ferrer Anna³,Notario Jaime⁴,Vidal David⁵,Riera José⁶,Aparicio Gloria⁷,Gallardo Fernando²,Vilarrasa Eva³,Alsina Mercè⁶,Puig Lluís³^ORCID,Ferrándiz Carlos¹,Carrascosa José M¹^ORCID

Affiliation:

1. Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain;

2. Department of Dermatology, Hospital del Mar- Institut Mar d’Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain;

3. Department of Dermatology, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain;

4. Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona (UB), L’Hospitalet de Llobregat, Spain;

5. Department of Dermatology, Hospital de Sant Joan Despi Moises Broggi, Sant Joan Despí, Spain;

6. Department of Dermatology, Hospital Clínic, Universitat de Barcelona (UB), Barcelona, Spain;

7. Department of Dermatology, Hospital Universitari Vall d’Hebrón, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2019.1597245

Reference11 articles.

1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

3. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

4. Annex I Summary of Product Characteristics. Eur. Med. Agency. Stel. Summ. Prod. Charact. 2009.

5. Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relación entre psoriasis y obesidad e implicaciones terapéuticas

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities;Expert Review of Clinical Pharmacology;2024-04-02

2. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab;Journal of Digestive Diseases;2024-04

3. Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics;European Journal of Dermatology;2023-10

4. The cardiometabolic conditions of psoriatic disease;Frontiers in Immunology;2022-09-08

5. A real life experience with ustekinumab: The effectiveness of 45 mg on patients greater than 80 kg but lower than 100 kg;Dermatologic Therapy;2022-04-10